Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Selexis Announces Expansion of R&D License Agreement with Amgen

Published: Friday, February 22, 2013
Last Updated: Thursday, February 21, 2013
Bookmark and Share
Expansion to include the Selexis SURE CHO-M Cell Line™.

Selexis SA has announced that Amgen has expanded their R&D License Agreement with Selexis to include an evaluation of the proprietary Selexis SURE CHO-M Cell Line™ for research and development.

Under the agreement, Amgen will be able to evaluate the SURE CHO-M Cell Line™ in conjunction with the Selexis SUREtech Vectors™ for improved R&D.

“Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding and stable,” said Igor Fisch, Ph.D., President and CEO of Selexis.

Fisch continued, “Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently. This current agreement is built on the long-standing relationship between our two companies since 2004.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selexis to Provide Preclinical Services in Support of Zyngenia’s Innovative Zybody™ Platform
Selexis have announced a strategic agreement with Zyngenia under which Selexis will utilize its' SURE Cell Line Development Platform™ to generate production cell lines for Zyngenia’s lead Zybody™ therapeutic programs.
Monday, November 15, 2010
Scientific News
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Paper Filter Can Remove Viruses from Water
A new paper filter can purify water from viruses, even the most difficult and contagious.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Mimicking Evolution to Create Novel Proteins
A study by researchers in the Kuhlman lab offers a new route to design the 'cellular machines' needed to understand and battle diseases.
Antibody Therapy Opens Door to Potential New Treatment for HIV
Researchers at Rockefeller University show how a broadly neutralizing antibody could be used to help fight HIV.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!